Administration Halts Peptide Compounding Penalties
The government will stop enforcement against pharmacies producing six specific peptides used for recovery and wellness.
Updated on Oct. 28, 2026 in Healthcare
Live Poll
Do you support the production of wellness products that have not completed rigorous FDA clinical trials?
The administration implemented an interim policy halting penalties for compounding pharmacies that produce six specific unapproved peptides. This shift reverses a 2023 ruling that previously banned the production of these substances.
Why it matters
The change allows for the legal compounding of products commonly used for muscle recovery, weight loss, and sleep improvement. This policy direction follows a push by Robert F. Kennedy Jr. to expand the availability of these substances.
The government is now allowing the production of six peptides, including BPC-157 and TB-500, which were previously prohibited. Following the policy update, Hims & Hers Health saw a 2.8% increase in its stock price.
The players
Robert F. Kennedy Jr.
He led the initiative to legalize the production of 14 peptides and restructured the FDA advisory committee to prioritize his preferred experts.
Hims & Hers Health
This company provides various health and wellness products and experienced a notable stock price increase following the policy announcement.
The details
The Office of Management and Budget enacted the change after Robert F. Kennedy Jr. restructured the FDA advisory committee to include experts with industry ties. Although an FDA advisory committee voted to reclassify these substances in July 2026, FDA staff members had recommended against the move.
Timeline
2023: The FDA made it illegal to compound certain peptides.
July 2026: An FDA advisory committee voted on peptide reclassification.
October 2026: The administration issued an interim policy on peptide production.
February 2027: A follow-up FDA advisory committee meeting is scheduled.
Market Landscape
This move signals a major shift in the regulatory environment for compounding pharmacies that had been constrained by the 2023 FDA ruling on peptide compounding. The decision reshapes market access for wellness-focused companies competing in the recovery and supplement sector.
Consumers may soon find greater availability of these peptides at compounding pharmacies as enforcement actions have ceased. While access expands, individuals should note that none of these six substances currently hold FDA approval.
The takeaway
The policy change marks a significant shift in how federal agencies regulate emerging wellness products. Readers should consult with licensed medical professionals regarding the safety and efficacy of unapproved substances.
What happens next
The FDA is scheduled to hold another advisory committee meeting in February 2027 to continue the formal reclassification review process for the peptides.
Further reading
For more information on industry regulations, visit the Healthcare section.
Live Poll
Do you support the production of wellness products that have not completed rigorous FDA clinical trials?
